交界性卵巢肿瘤:法国CNGOF指南。第一部分:流行病学、生物病理学、影像学和生物标志物
该指南由法国国家妇产科医师学院(CNGOF)制定,涵盖交界性卵巢肿瘤的流行病学、病理分类、影像诊断与生物标志物应用。推荐经阴道和耻骨上超声作为卵巢肿块分析的一线检查(Grade A),超声不确定时行盆腔MRI(Grade A),MRI应采用包含T2、T1、T1脂肪抑制、动态和扩散序列及钆注射的方案(Grade B),并建议在报告中纳入恶性评分系统(ADNEX MR/O-RADS)(Grade C)。
要点
- 经阴道和耻骨上超声推荐用于卵巢肿块分析(Grade A);超声不确定时推荐盆腔MRI(Grade A)。
- 疑似交界性卵巢肿瘤的MRI推荐采用T2、T1、T1脂肪抑制、动态和扩散序列及钆注射方案(Grade B)。
- MRI报告中建议纳入恶性评分系统(ADNEX MR/O-RADS)并形成组织学假设(Grade C)。
关键影像表现/征象
- MRI宏观特征应被分析以区分交界性卵巢肿瘤亚型(Grade C)。
- 对于疑似交界性卵巢肿瘤的肿瘤,推荐盆腔MRI进行表征(Grade C)。
诊断标准与关键数值
- 经阴道和耻骨上超声推荐用于卵巢肿块分析(Grade A)。
- 超声显示不确定的卵巢病变时,推荐行盆腔MRI(Grade A)。
- MRI分析附件肿块推荐采用包含T2、T1、T1脂肪抑制、动态和扩散序列以及钆注射的方案(Grade B)。
- MRI表征附件肿块建议在报告中纳入恶性评分系统(ADNEX MR/O-RADS)(Grade C)并形成组织学假设(Grade C)。
- 妊娠期附件肿块的检测和表征首选盆腔超声(Grade C);妊娠12周起超声不确定的附件肿块推荐盆腔MRI并提供诊断评分(Grade C)。
临床应用与阅片要点
- 对卵巢肿块首选经阴道和耻骨上超声分析(Grade A);超声不确定时行盆腔MRI(Grade A)。
- MRI方案应包括T2、T1、T1脂肪抑制、动态和扩散序列及钆注射(Grade B),报告中建议纳入ADNEX MR/O-RADS评分并形成组织学假设(Grade C)。
- 疑似交界性卵巢肿瘤的肿瘤推荐盆腔MRI表征(Grade C),并分析MRI宏观特征以区分亚型(Grade C)。
- 妊娠期附件肿块首选盆腔超声(Grade C),妊娠12周起超声不确定者推荐MRI并给出诊断评分(Grade C),钆注射必须最小化(Grade C)。
- 影像学怀疑黏液性交界性卵巢肿瘤时可考虑检测血清CA 19-9水平(Grade C)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The incidence (rate per 100 000) of borderline ovarian tumors (BOTs) increases progressively with age, starting at 15-19 years and peaking at around 4.5 cases per 100 000 at an age of 55-59 years (LE3) with a median age of 46 years. The five year survival for FIGO stages I, II, III and IV is 99.7 % (95 % CI: 96.2-100 %), 99.6 % (95 % CI: 92.6-100 %), 95.3 % (95 % CI: 91.8-97.4 %) and 77.1 % (95 % CI: 58.0-88.3 %), respectively (LE3). An epidemiological association exists between the individual risk of BOT and family history of BOT and certain other cancers (pancreatic, lung, bone, leukemia) (LE3), a personal history of benign ovarian cyst (LE2), a personal history of tubo-ovarian infection (LE3), the use of a levonorgestrel intrauterine device (LE3), oral contraceptive use (LE3), multiparity (LE3), Hormonal replacement therapy (LE3), high consumption of Coumestrol (LE4), medical treatment for infertility with progesterone (LE3) and non-steroidal anti-inflammatory drug use (LE3). Screening for BOTs is not recommended for patients (Grade C). The overall risk of recurrence of BOTs varies between 2% and 24 %, with an overall survival greater than 94 % at 10 years, and the risk of an invasive recurrence of a BOT ranges from 0.5 % to 3.8 %. The use of scores and nomograms can be useful in assessing the risk of recurrence, and providing patients with information (Grade C). The WHO classification is recommended for classifying BOTs. It is recommended that the presence of a microinvasive focus (<5 mm) and microinvasive carcinoma (<5 mm with an atypical nuclei and a desmoplastic stroma reaction) within a BOT be reported. In cases of serous BOT, it is recommended to specify the classic histological subtype or micropapillary / cribriform type (Grade C). When confronted with a BOT, it is recommended that the invasive or non-invasive nature of peritoneal implants can be investigated based solely on the invasion and destruction of underlying adipose or peritoneal tissue which has a desmoplastic stromal reaction where in contact with the invasive clusters (Grade B). For bilateral mucinous BOTs and / or in cases with peritoneal implants or peritoneal pseudomyxoma, it is recommended to also look for a primitive digestive or pancreato-biliary cancer (Grade C). It is recommended to sample ovarian tumors suspected of being BOTs by focusing samples on vegetations and solid components, with at least 1 sample per cm in tumors with a size less than 10 cm and 2 samples per cm in tumors with a size greater than 10 cm (Grade C). In cases of BOTs and in the absence of macroscopic omental involvement after careful macroscopic examination, it is recommended to perform at least 4-6 systematic sampling blocks and to include all peritoneal implants (Grade C). It is recommended to consult an expert pathologist in gynecology when a BOT suspicion requires intraoperative extemporaneous histology (grade C). Endo-vaginal and suprapubic ultrasonography are recommended for the analysis of an ovarian mass (Grade A). In case of an undetermined ovarian lesion on ultrasonography, it is recommended that a pelvic MRI be performed (Grade A). To analyze an adnexal mass with MRI, it is recommended to use an MRI protocol with T2, T1, T1 Fat Sat, dynamic and diffusion sequences as well as gadolinium injection (Grade B). To characterize an adnexal mass with MRI, it is recommended to include a score system for malignancy (ADNEX MR/O-RADS) (Grade C) in the report and to formulate a histological hypothesis (Grade C). Pelvic MRI is recommended to characterize a tumor suspected of being a BOT (Grade C). Macroscopic MRI features should be analyzed to differentiate BOT subtypes (Grade C). Pelvic ultrasound is the first-line examination for the detection and characterization of adnexal masses during pregnancy (Grade C). Pelvic MRI is recommended from 12 weeks of gestation in case of an indeterminate adnexal mass and should provide a diagnostic score (Grade C). Gadolinium injection must be minimized as fetal impairment has been proven (Grade C). It is recommended that serum levels of HE4 and CA125 be evaluated and that the ROMA score for the diagnosis of an indeterminate ovarian mass on imaging be used (grade A). In case of suspicion of a mucinous BOT on imaging, dosage of serum levels of CA 19-9 can be considered (Grade C). If the determination of tumor markers is normal preoperatively, routine dosage of tumor markers in BOT follow-up is not recommended (Grade C). In case of preoperative elevation in tumor markers, the determination of serum CA 125 levels is recommended in the follow-up of BOT (Grade B). When conservative treatment of a BOT has been adopted, the use of endovaginal and transabdominal ultrasonography is recommended during follow-up (Grade B).
引用
- Huchon C, Bourdel N, Abdel Wahab C, et al. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers. J Gynecol Obstet Hum Reprod. 2020. PMID: 33160106. doi:10.1016/j.jogoh.2020.101965
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。